In a pharma alliances deal, Bayer HealthCare has agreed with Amgen Research to develop and commercialize another new Bispecific T cell Engager antibody against an undisclosed target expressed in multiple tumors.
Under this pharma alliances agreement, Bayer will collaborate with Amgen Research in Munich from the research phase through the completion of Phase I clinical trials, upon which Bayer will assume full control of further development and commercialization of the product candidate.
According to The Bayer Group, the cooperation also includes evaluation of BiTE antibodies with an extended serum half-life.
Financial details of the pharma alliances collaboration were not disclosed.
The development of the initial BiTE antibody resulting from the 2009 collaboration progresses according to plan and the initiation of the clinical Phase I trial could start as early as in the second half of 2012.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity